Opyl Limited provided earnings guidance for the fiscal second half of 2023. Opyl is also anticipating further revenue contract wins stemming from these MSAs and other opportunities in the sales pipeline, which implies a stronger 2HFY23 for the Company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.026 AUD | +4.00% |
|
+13.04% | -7.14% |
06-06 | Opyl Secures First TrialGen Contract with Brain Vector | MT |
04-29 | Opyl Expands TrialKey Coverage; Shares Up 38% | MT |
1st Jan change | Capi. | |
---|---|---|
-7.14% | 2.83M | |
-3.30% | 30.09B | |
+44.11% | 9.91B | |
+36.91% | 4.52B | |
-36.88% | 2.39B | |
-8.48% | 1.62B | |
-29.26% | 1.22B | |
+6.61% | 953M | |
-45.05% | 936M | |
-46.72% | 732M |
- Stock Market
- Equities
- OPL Stock
- News Opyl Limited
- Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023